



Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

April 2, 2026

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- [Relay Therapeutics, Inc.](https://www.relaytx.com) (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 19-22, 2026, in Philadelphia. The company anticipates reporting clinical data on approximately 20 efficacy-evaluable patients.

Late Breaking Clinical Abstract:

Abstract Title: Initial Results of Zovegalisib (RLY-2608), a Mutant-selective PI3K α Inhibitor in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations

Abstract Number: 488

Session: Late Breaking Abstract Session

Date/Time: Wednesday, May 20, 4:30 p.m. ET

Preclinical Abstract:

Abstract Title: Zovegalisib (RLY-2608), a Novel, Mutant-selective, PI3K α Inhibitor, Induces Lesion Regression, with Minimal Hyperinsulinemia, in Murine Models of PIK3CA-mutant Vascular Malformations

Abstract Number: 404

Session: Session 9 - Combined

Date/Time: Friday, May 22, 11:10 a.m. ET

The presentations will be available at the start of the sessions on the company's website at <https://relaytx.com/publications/>.

About Zovegalisib

Zovegalisib is the lead program in Relay Therapeutics' efforts to discover and develop mutant-selective inhibitors of PI3K α , the most frequently mutated kinase in all cancers and all vascular anomalies. Zovegalisib has the potential, if approved, to address a significant portion of the approximately 140,000 patients with HR+/HER2- breast cancer with a PI3K α mutation and the estimated 170,000 patients with vascular anomalies driven by a PI3K α mutation per year in the United States, one of the largest patient populations for a precision medicine.

Traditionally, the development of PI3K α inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3K α and off-isoform activity. Toxicity related to inhibition of WT PI3K α and other PI3K isoforms results in sub-optimal inhibition of mutant PI3K α with reductions in dose intensity and frequent discontinuation. The Dynamo[®] platform enabled the discovery of zovegalisib, the first known allosteric, pan-mutant, and isoform-selective PI3K α inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3K α , performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3K α , and leveraged these insights to support the design of zovegalisib. Zovegalisib is currently being evaluated in multiple metastatic breast cancer studies and a Phase 1/2 study designed to treat patients with PIK3CA (PI3K α) mutation driven vascular anomalies. For more information on zovegalisib, please visit [here](https://www.relaytx.com).

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo[®] platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company's lead clinical asset, zovegalisib, is the first pan-mutant selective PI3K α inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3K α -driven vascular anomalies. Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or [follow us on LinkedIn](#).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the timing of clinical data readouts for zovegalisib; the expected therapeutic benefits and potential efficacy and tolerability of zovegalisib, both as a monotherapy and in combination with other agents, and its other programs; the clinical data for zovegalisib; the interactions with regulatory authorities and any related approvals; and the potential commercialization and market opportunity for zovegalisib. The words "may," "might," "will," "could," "would," "should," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contact:

Pete Rahmer

prahmer@relaytx.com

Media:

Dan Budwick

1AB

973-271-6085

dan@1abmedia.com